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Abstract
Background: Despite of the fact that mammalian genomes are far more spacious than prokaryotic
genomes, recent nucleotide sequencing data have revealed that many mammalian genes are
arranged in a head-to-head orientation and separated by a small intergenic sequence. Extensive
studies on some of these neighboring genes, in particular homologous gene pairs, have shown that
these genes are often co-expressed in a symmetric manner and regulated by a shared promoter
region. Here we report the identification of two non-homologous brain disease-related genes, with
one coding for a serine protease inhibitor (SERPINI1) and the other for a programmed cell death-
related gene (PDCD10), being tightly linked together by an asymmetric bidirectional promoter in
an evolutionarily conserved fashion. This asymmetric bidirectional promoter, in cooperation with
some cis-acting elements, is responsible for the co-regulation of the gene expression pattern as well
as the tissue specificity of SERPINI1 and PDCD10.
Results: While SERPINI1 is predominantly expressed in normal brain and down-regulated in brain
tumors, PDCD10 is ubiquitously expressed in all normal tissues but its gene transcription becomes
aberrant in different types of cancers. By measuring the luciferase activity in various cell lysates,
their 851-bp intergenic sequence was shown to be capable of driving the reporter gene expression
in either direction. A 175-bp fragment from nt 1 to 175 in the vicinity of PDCD10 was further
determined to function as a minimal bidirectional promoter. A critical regulatory fragment, from
nt 176-473 outside the minimal promoter in the intergenic region, was identified to contain a
strong repressive element for SERPINI1 and an enhancer for PDCD10. These cis-acting elements
may exist to help coordinate the expression and regulation of the two flanking genes.
Conclusion: For all non-homologous genes that have been described to be closely adjacent in the
mammalian genomes, the intergenic region of the head-to-head PDCD10-SERPINI1  gene pair
provides an interesting and informative example of a complex regulatory system that governs the
expression of both genes not only through an asymmetric bidirectional promoter, but also through
fine-tuned regulations with some cis-acting elements.
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Background
In the human genome, there are over 550 genes coding for
proteases with another 150 being protease inhibitors [1].
While the majority of protease genes belong to three dif-
ferent classes including serine, metallo- and cysteine pro-
teases, a large portion (~25%) of human protease
inhibitor genes belong solely to just one family: the serpin
family.
The serpin family comprises hundreds of structurally
homologous proteins that are present in both eukaryotic
and prokaryotic organisms [2-4]. Its members include
inhibitors of serine proteases as well as non-inhibitory
members with other biological functions [5]. In humans,
a total of 35 serpin-coding genes were identified and
grouped into 9 subfamilies designated SERPINA,  SER-
PINB, SERPINC and so on till SERPINI subfamily [2,3].
Each subfamily has its own specific chromosomal locali-
zation and well-conserved exon-intron arrangement. For
example, nearly all members of the SERPINA subfamily
are located at chromosome 14q32 and genes coding for
the SERPINB subfamily are clustered at two distinct chro-
mosomal loci: 6p25 and 18q21 [6-9]. Even for the last
SERPINI subfamily, although consists of only two genes
with one coding for a brain-associated protease inhibitor
SERPINI1 [10] and another for a pancreas-specific pro-
tease inhibitor SERPINI2 [11], its two members are closely
adjacent at chromosome 3q26 and share a perfectly con-
served gene organization pattern [12].
SERPINI1, also known as neuroserpin or protease inhibi-
tor 12, is an axonally secreted serine protease inhibitor
found in the nervous systems [10]. It functions as a selec-
tive inhibitor of tissue-type plasminogen activator and is
involved in a wide range of neuronal processes including
synaptic plasticity [10,13], neuronal migration [14,15]
and axogenesis [15,16]. Genetic variations of SERPINI1
have been reported to render the enzyme conformation
locked as an inactive folding intermediate [17-20]. These
mutant proteins then undergo spontaneous polymeriza-
tion within neurons and cause a severe progressive neuro-
degenerative encephalopathy named FENIB (familial
encephalopathy with neuroserpin inclusion bodies)
[21,22]. In addition to the mutations at the DNA level, the
mRNA expression of SERPINI1 was found to be down-reg-
ulated or lost in brain tumors [12]. These abnormalities,
along with our latest findings that its adjacent gene
SERPINI2  is also down-regulated in cancer [12],
prompted us to study the regulatory mechanism of
SERPINI1 gene in both normal and cancerous brain tis-
sues. Interestingly, when the human genome sequence
became available, it came to our attention that a gene
termed  PDCD10  was mapped to lie at less than 1 kb
upstream of SERPINI1 in a divergent, head-to-head orien-
tation.
PDCD10 was originally identified as TFAR15 (TF-1 cell
apoptosis related gene-15) for being up-regulated after the
induction of apoptosis by serum withdrawal in TF-1
human premyeloid cells [23]. It was later grouped into a
collection of genes thought to be involved in many apop-
totic responses and thus renamed as PDCD10  (pro-
grammed c ell death 10 gene). PDCD10  is highly
conserved among different species, with over 99% amino-
acid identity among human, dog, mouse and chicken.
Although its physiological role remains unclear, a recent
study showed that inhibition of the nematode PDCD10
ortholog led to embryonic lethality in 40% of the
embryos and a dumpy phenotype in postembryonic via-
ble embryos [24]. Furthermore, PDCD10 mutations were
identified in families with cerebral cavernous malforma-
tion, indicating that this gene may play a role in the devel-
opment of cerebral vascular morphogenesis [25].
It is known that in prokaryotic and lower eukaryotic
genomes, genes are often organized in a proximal pattern
to facilitate gene co-expression and functional coupling.
Increasing evidence suggests that many genes in mamma-
lian genomes also tend to be in close physical vicinity.
Recently, by conducting a genome-wide analysis of the
human genome, Trinklein and his colleagues identified a
class of head-to-head gene pairs whose transcriptional
start sites are separated by less than 1 kb [26]. Since mam-
malian genomes are far more spacious than prokaryotic
genomes, it seems unnecessary for two neighboring genes
to be arranged in an adjacent head-to-head pattern unless
they share a common regulatory system such as an inter-
genic bidirectional promoter. It is conceivable that bidi-
rectional promoters of gene pairs may be able to co-
regulate the genes in a more efficient manner. For exam-
ple, for homologous gene pairs such as the pair of colla-
gen type IV α1 and α2 genes [27] and the pair of ATP-
binding cassette molecule ABCG5  and  ABCG8  genes
[28,29], their bidirectional promoters were shown to co-
regulate the two genes thus ensuring the co-expressivity of
the gene products. For non-homologous genes like
SERPINI1 and PDCD10, however, the need for co-regula-
tion is not as obvious. In addition, compared to all the
other genes that are adjacently located to any of known
SERPIN or PDCD genes, only the pair of SERPINI1 and
PDCD10 genes were arranged in a head-to-head orienta-
tion and separated by an exceptionally short intergenic
region. This close chromosomal proximity of SERPINI1
and PDCD10 and their divergent configuration are widely
preserved in many species, implying that through the evo-
lution there appears to have a need for SERPINI1  and
PDCD10 to be tightly linked together to maintain gene co-
regulation or functional association.
In this study, we present evidence showing that while
SERPINI1 is predominantly expressed in brain and down-BMC Molecular Biology 2007, 8:2 http://www.biomedcentral.com/1471-2199/8/2
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regulated in brain tumors, PDCD10  is ubiquitously
expressed in all normal tissues but its gene transcription
becomes aberrant in different types of cancers. We have
also identified a 175-bp regulatory fragment within the
intergenic region of SERPINI1  and PDCD10  that func-
tions as a bidirectional promoter. Moreover, a critical frag-
ment, from nt 176-473 outside the minimal promoter in
this intergenic region, was found to possess a strong
repressive activity for SERPINI1 and enhancing activity for
PDCD10. These cis-acting elements may exist to coordi-
nate the expression and regulation of the two flanking
genes. To the best of our knowledge, of all non-homolo-
gous genes that have been reported to be closely adjacent
in the human genome, the intergenic region of the head-
to-head PDCD10-SERPINI1 pair at 3q26 exhibits by far
the most complex regulatory function that governs the
expression of both genes not only through an asymmetric
bidirectional promoter, but also through regulations with
some other cis-acting elements.
Results
Expression patterns of SERPINI1 and PDCD10 in normal 
and cancerous tissues
In order to explore the distribution patterns of SERPINI1
and PDCD10, we performed Northern blot analysis on a
human multiple tissue expression array of poly A+ RNAs.
As illustrated in Fig. 1, while SERPINI1 expression was
observed mainly in different parts of brain, hybridization
of the same array with the PDCD10 probe revealed that it
was ubiquitously expressed as a housekeeping gene in all
tissues analyzed. Moreover, as SERPINI1 and SERPINI2
were both reported to be down-regulated during tumor
development [12], it is rational to doubt that the expres-
sion of PDCD10, which is located in between the two SER-
PINI genes at chromosome 3q26, may also be altered in
some tumors. Results from the semi-quantitative RT-PCR
indicate that while SERPINI1 expression was negatively
correlated with tumor progression, the mRNA level of
PDCD10 was not much affected in brain tumor cells (Fig.
2). Furthermore, when we investigated the expression pat-
terns of PDCD10 in other normal and cancerous tissues,
we found that PDCD10 was up-regulated in various can-
cers including ovarian, stomach, lung, uterus and small
intestine cancers (Fig. 2)
Determination of the distance of the intergenic region 
between human SERPINI1 and PDCD10 genes
After analyzing the distribution of mRNA transcripts for
both SERPINI1 and PDCD10 genes, we then attempted to
pinpoint their precise transcriptional start sites in order to
determine the length of their intergenic spacer. As
revealed by the human genome reference sequence,
SERPINI1  [accession number EMBL:BC018043] and
PDCD10  [accession number EMBL:AF022385] were
mapped in a head-to-head configuration at 3q26 and sep-
arated by less than 1 kb. By performing 5'-RACE on
human brain RNA, three transcriptional start sites for
PDCD10  but only one transcriptional start site for
SERPINI1 were identified. The closest transcriptional start
site that we identified for PDCD10 and SERPINI1 were at
5 and 15 bp respectively upstream of the sites predicted by
NCBI database, thus the shortest intergenic distance was
recalculated to be 851 bp (Fig. 3 & 4).
Characterization of the asymmetric bidirectional 
promoter activity of the intergenic region
Following the mapping of the transcriptional start sites,
the 851-bp intergenic fragment constituting the putative
regulatory region for both SERPINI1 and PDCD10 genes
was analyzed for its transcriptional activities by driving
the firefly luciferase reporter gene. The human cell lines
utilized for luciferase reporter assays include brain neuro-
glioma H4, brain glioblastoma U-87 MG, ovarian adeno-
carcinoma OVTW-59-4, lung adenocarcinoma CL1-5, and
cervical adenocarcinoma HeLa cancer cell lines. The rat
adrenal gland pheochromocytoma PC-12 cell line was
also used for comparison as it had previously been chosen
for the study of mouse Serpini1 promoter [30]. The full-
length 851-bp fragments in either direction toward
SERPINI1 or PDCD10 were cloned into the reporter vector
(pGL3-Basic). By measuring the luciferase activity in vari-
ous cell lysates after transient transfection, the 851-bp
intergenic sequence was shown to be capable of driving
the reporter gene expression in either direction (Fig. 3).
The promoter activities in the direction of PDCD10 in all
cells tested were approximately 4 to 10-fold higher than
those of SERPINI1. Moreover, the promoter activities
toward the SERPINI1  direction were higher in brain
tumor H4 and U-87 MG cells than those in other test cells,
and they were nearly 3-fold higher than the positive con-
trol, the viral SV40 minimal promoter (Fig. 3). These
results indicate that the 851-bp intergenic region is able to
function as a bidirectional promoter to control SERPINI1
and PDCD10 expressions, and some regulatory elements
within this region may asymmetrically regulate the tran-
scription of both genes.
Interspecies comparison of the 851-bp intergenic region 
and analysis of the putative cis-regulatory elements within 
this region
To understand whether the head-to-head configuration of
SERPINI1 and PDCD10 is a unique feature only in human
or if it is evolutionary conserved in other mammals, we
aligned the homologous regions between these two genes
among human, mouse and rat by the Vector NTI program
(InforMax, Bethesda, MD, USA). The results revealed that
both the gene order and the compact head-to-head
arrangement are conserved in different species (data not
shown), and that within the intergenic region there is an
approximately 400-bp fragment near the vicinity ofBMC Molecular Biology 2007, 8:2 http://www.biomedcentral.com/1471-2199/8/2
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PDCD10 with the highest percent identity (Fig. 4A). Based
on the nucleotide sequence shown in Fig. 4B, the 851-bp
intergenic region has a GC content of 65%, which is much
higher than the average of the entire human genome
(41%). While no TATA-box is observed in this region, two
CAAT boxes (consensus GGT/CCAATCT) are noted in the
most conserved 400-bp fragment with a 100-bp distance
from each other. In addition, within this highly conserved
fragment, there are one neuron-specific AP-2, one c-Myc
and one NFκB binding motives as well as several binding
sites for the general transcription factor Sp1 as predicted
by MatInspector (Genomatix; http://www.genomatix.de)
and TFSEARCH programs (Computational Biology
Research Center; http://www.cbrc.jp). The presence and
conservation of these putative binding motives suggest
that some of these transcription factors must possess an
important evolutionary significance and some yet-
unknown regulatory demands.
Identification of the key regulatory region of the 
bidirectional promoter by deletion analysis
To identify the key regulatory DNA sequences responsible
for  SERPINI1  and  PDCD10  gene expressions, we con-
structed a series of plasmids containing various intergenic
promoter regions derived from the 851-bp sequence. By
using the same reporter system addressed in Fig. 3, the
luciferase activities of these constructs were assessed by
transient transfection into H4 cells. Due to the neuron-
specific expression of the SERPINI1 gene, the promoter
activity of SERPINI1 in neuron cells is higher than those
in cells from other tissues. Thus, H4 cells were used as a
vehicle for studying the regulatory mechanism of
SERPINI1 promoter. As shown in Fig. 5, removal of the
Northern blot analysis of SERPINI1 and PDCD10 in various tissues Figure 1
Northern blot analysis of SERPINI1 and PDCD10 in various tissues. Human MTE multiple tissue expression array II 
(BD Clontech) was hybridized with 32P-labeled probe against A) SERPINI1, B) PDCD10, and C) control ubiquitin, respectively. 
Panel D shows the individual designations of all tissues examined.BMC Molecular Biology 2007, 8:2 http://www.biomedcentral.com/1471-2199/8/2
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sequence from nt 1 to 175 completely abolished luciferase
activity compared to the full-length 851-bp fragment in
the SERPINI1 direction, suggesting that this 175-bp frag-
ment is important for the control of SERPINI1  gene
expression. This fragment alone was also capable of driv-
ing the reporter gene expression in the PDCD10 direction.
Further splitting of this bidirectional promoter region into
two parts, i.e. the sequence from nt 1 to 107 or from nt
108 to 175, resulted in a dramatic loss of luciferase activ-
ity. Surprisingly, deletion of the fragment of nt 176 to 851
increased more than 3-fold of the luciferase activity rela-
tive to that of the 851-bp fragment in the SERPINI1 direc-
tion but only kept a ~40% remaining of the luciferase
activity in the PDCD10 direction (Fig. 5). These results
strongly indicate that within the fragment of nt 176-851
there likely exist a repressive element that can regulate
SERPINI1 expression and an enhancer that can modulate
PDCD10  expression. Based on these findings, we con-
clude that a 175-bp minimal promoter region from nt 1 to
175 near the vicinity of PDCD10 and a regulatory region
outside the 175-bp fragment from nt 176 to 851 may
coordinately regulate the gene transcriptions of SERPINI1
and PDCD10.
Possible locations of the repressive element for SERPINI1 
and the enhancer for PDCD10
From the experiment described in Fig. 5, there seems to
exist a regulatory fragment from nt 176 to 851 which pos-
sesses no promoter activity but appears to contain a
repressive element for SERPINI1  and an enhancer for
PDCD10. Thus, we cloned this fragment in two opposite
directions into the upstream of the SV40 promoter in a
pGL3-Promoter vector, and examined their effects on the
SV40 promoter. As expected, the fragment of nt 176-851
in the PDCD10 direction was able to increase the SV40
promoter activity for approximately 2.2-fold (Fig. 6A).
Relative expression levels of SERPINI1 and PDCD10 between normal and tumorous tissues Figure 2
Relative expression levels of SERPINI1 and PDCD10 between normal and tumorous tissues. A) Semi-quantitative 
RT-PCR analysis of SERPINI1 and PDCD10 transcripts. RNAs used in this study were obtained from the normal human brain 
(Lanes 2, 6 & 10), human neuroglioma H4 cells (Lanes 3, 7 & 11) and human glioblastoma U-87 MG cells (Lanes 4, 8 & 12). M 
indicates the DNA size markers; and Lanes 1, 5 & 9 are the negative controls without templates in the PCR reactions. B & C) 
Northern hybridization analysis of PDCD10 (B) and ubiquitin (C) in paired normal/tumor tissue samples (BD Clontech). The 
array order of all tissues examined is shown in panel D.BMC Molecular Biology 2007, 8:2 http://www.biomedcentral.com/1471-2199/8/2
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This observation confirmed the existence of an enhancer
for PDCD10  as seen in Fig. 5. However, there was no
increase of the SV40 promoter activity in the direction of
SERPINI1. This phenomenon was possibly a compromis-
ing effect resulted from the coordination between the
enhancer and the repressive element within the regulatory
region; the extent of such effect may also vary for using
different heterologous promoters.
To further identify the enhancer responsible for PDCD10,
three intergenic fragments including 1) the nt 176-473
fragment, 2) the nt 474-710 fragment, and 3) the nt 711-
851 fragment toward the PDCD10 direction were individ-
ually cloned into the upstream of the SV40 promoter and
assayed for their promoter activity in H4 cells. The results
showed that only the nt 473-176 fragment was able to
increase the SV40 promoter activity by 6 to 10-fold (Fig.
6B). The same fragment toward the SERPINI1 direction
Analysis of the intergenic distance between PDCD10 and SERPINI1 and its promoter activity in various cell lines Figure 3
Analysis of the intergenic distance between PDCD10 and SERPINI1 and its promoter activity in various cell 
lines. A) The intergenic distance between PDCD10 and SERPINI1 was 851 bp, as determined from the results of 5'-RACE. The 
nucleotides between the two closest transcriptional start sites of PDCD10 and SERPINI1 are numbered from the centromeric 
(cen) end to the telomeric (tel) end. B) The promoter activity of the intergenic 851-bp fragment in either direction (toward 
PDCD10 or SERPINI1) was determined by the firefly luciferase assay in 6 different cell lines including human neuroglioma H4, 
human brain glioblastoma U-87 MG, human ovarian adenocarcinoma OVTW-59-4, human lung adenocarcinoma CL1-5, human 
cervical adenocarcinoma HeLa, and rat adrenal gland pheochromocytoma PC-12 cells.BMC Molecular Biology 2007, 8:2 http://www.biomedcentral.com/1471-2199/8/2
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Sequence analysis of the intergenic region of the divergent PDCD10-SERPINI1 gene pair Figure 4
Sequence analysis of the intergenic region of the divergent PDCD10-SERPINI1 gene pair. Dot matrix alignment of 
the intergenic sequence of the human PDCD10-SERPINI1 pair with those of mouse (A) and rat (B). The units in both vertical 
and horizontal axis are the position numbers of the nucleotides in the intergenic region as shown in Fig. 3A. C) The complete 
nucleotide sequence of the intergenic spacer between human PDCD10 and SERPINI1. The putative transcription factor binding 
sites are underlined. The transcriptional start sites confirmed by 5'-RACE are indicated by bended arrows. The shaded nucle-
otides indicate the transcriptional start sites of the reference sequence reported by the NCBI database. The arrowheads indi-
cate the cutting sites for the deletion assays described in Fig. 5.BMC Molecular Biology 2007, 8:2 http://www.biomedcentral.com/1471-2199/8/2
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had no such effect on the SV40 promoter activity (data not
shown). Hence, there is an orientation-dependent
enhancer located in the fragment of nt 176-473 and acting
on the transcription of PDCD10. As for the search of the
repressive element for SERPINI1, the same fragments but
in opposite direction were individually cloned into a
modified pGL3-Promoter vector containing a CMV pro-
moter, a stronger promoter than the SV40 and better for
repressive activity studies. The assay results demonstrated
that only the fragment from nt 176-473 toward the
SERPINI1 direction possessed a repressive ability which
inhibited ~70% of the CMV promoter activity (Fig. 6C).
Nonetheless, the same fragment but in the opposite orien-
tation (toward the PDCD10  direction) could only
enhance the CMV promoter activity for approximately 2-
fold (data not shown). These findings signify that a critical
fragment from nt 176-473 outside the minimal promoter
possesses a strong repressive activity for SERPINI1 and
enhancing activity for PDCD10.
Discussion
It has long been suggested that the human serpin genes
are evolved from the same ancestor through intra- and
interchromosomal duplications to develop into different
clusters [31-33]. Interestingly, when the human genome
sequence was unveiled a few years ago, several non-
homologous genes were found to be mapped into the ser-
pin gene clusters. One of these genes, PDCD10, not only
forms a head-to-head organization with SERPINI1  at
chromosome 3q26 but also shares a tiny promoter with it.
The organization of this divergent gene pair is well pre-
served in many species throughout the evolution, indicat-
ing that PDCD10  and  SERPINI1  need to be tightly
together to maintain the gene co-regulation or their func-
Identification of the minimal bidirectional promoter region of the PDCD10-SERPINI1 gene pair Figure 5
Identification of the minimal bidirectional promoter region of the PDCD10-SERPINI1 gene pair. The 5'- and 3'-
deleted putative promoter fragments were individually cloned into the upstream of the firefly luciferase gene (LUC) in the 
pGL3-Basic vector followed by transient transfection into human neuroglioma H4 cells. The pRL-TK plasmid carrying Renilla 
luciferase gene was co-transfected as the internal control. The relative firefly luciferase activities were normalized to the Renilla 
luciferase activities to correct the transfection efficiency. The length and the position of each promoter insert are shown in 
scale. The numbers denote the positions of nucleotides with respect to +1, the first intergenic nucleotide next to the tran-
scriptional start site of PDCD10, and +851, the intergenic nucleotide right next to the transcriptional start site of SERPINI1. The 
empty boxes represent inserted intergenic sequences. The shaded boxes represent the SV40 promoter.BMC Molecular Biology 2007, 8:2 http://www.biomedcentral.com/1471-2199/8/2
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Identification of the enhancer and the repressive element within the intergenic region of the PDCD10-SERPINI1 gene pair Figure 6
Identification of the enhancer and the repressive element within the intergenic region of the PDCD10-
SERPINI1 gene pair. Various intergenic fragments were cloned upstream of either the SV40 or CMV promoter and of a luci-
ferase reporter gene in the pGL3 vector. All constructs were transiently transfected into human neuroglioma H4 cells and the 
luciferase activity was measured. The resulting promoter activity was calculated relative to the control SV40 or CMV promoter 
activity which is artificially set at 100. A) The potential regulatory sequences from nt 176 to 851 of the intergenic region were 
cloned upstream of the SV40 promoter and their effects on the activity of the SV40 promoter were examined. B) Three inter-
genic fragments (nt 851-711, nt 710-474 and nt 473-176) in the PDCD10 direction were individually cloned upstream of the 
SV40 promoter to assess their effects on the activity of the SV40 promoter. C) Three different intergenic fragments (nt 711-
851, nt 474-710 and nt 176-473) in the SERPINI1 direction were individually cloned upstream of the CMV promoter in a modi-
fied pGL3-Promoter vector. Their effects on the activity of the CMV promoter were then investigated. The numbering system 
for nucleotide position is the same as those described in Fig. 5. The length and the position of each promoter insert are shown 
in scale. In the names of constructs, S denotes the SV40 promoter and C denotes the CMV promoter.BMC Molecular Biology 2007, 8:2 http://www.biomedcentral.com/1471-2199/8/2
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tional association. Further sequence analysis on the inter-
genic region revealed a 400-bp fragment near the vicinity
of PDCD10 is highly similar among human, mouse and
rat, a result strongly indicating that the transcriptional reg-
ulation mechanisms of these two genes are evolutionary
conserved among different species. Indeed, by performing
a series of luciferase assays, a 175-bp fragment from nt 1
to 175 in the vicinity of PDCD10 was determined to func-
tion as a minimal promoter of both genes (Fig. 5). The
same 175-bp minimal promoter was also observed (data
not shown) when we utilized the human intergenic frag-
ment to perform the promoter analysis in rat adrenal
gland PC12 cells [30]. In addition, we detected the exist-
ence of an important regulatory fragment from nt 176 to
473 in the vicinity of PDCD10 that possesses a repressive
activity for SERPINI1 (Fig. 6). These findings are different
from a previous study on mouse Serpini1 [30] claiming
that a 200-bp segment near the transcription initiation
site of Serpini1  was responsible for promoter activity.
There are at least two possible reasons for the discrepancy
observed in human and mouse SERPINI1 promoter. First,
the constructs used for promoter analysis of mouse
Serpini1  were all derived from 5' deletions of the full-
length promoter region. These constructs might have con-
tained the repressive element and/or lost the minimal
promoter, and thus have very low promoter activities
which could not be differentiated from each other. Sec-
ondly, different cell lines chosen might result in different
conclusions; particularly the rat adrenal gland cell line
PC12 has very low expression of Serpini1.
Trinklein and colleagues have pointed out that diver-
gently transcribed gene pairs whose transcriptional start
sites are separated by less than 1 kb represent more than
10% of genes in the whole human genome [26]. Such a
high proportion indicates that there is a biological impor-
tance for those adjacent gene pairs even through a long
evolution. Two feasible explanations for the existence of
bidirectional promoters in the mammalian genome were
recently given by Zhang and colleagues [34]. The first
explanation is that they are the ancestral sequences sur-
vived in evolution. A bidirectional promoter, like the one
for  PDCD10  and  SERPINI1, with the characteristics of
TATA-less, GC-rich and multiple Sp1 sites was thought to
be the preserved ancestral sequences. The second explana-
tion is that the genes sharing the bidirectional promoter
are functionally related. From the sequence alignment
data, we observed that this highly conserved promoter
sequence is maintained throughout the evolution.
Besides, there are evidences indicating that PDCD10 and
SERPINI1 are both related to brain diseases. Therefore, we
suggest that the compact adjacent arrangement for
PDCD10 and SERPINI1 might be due to the possibility
that they are involved in the same biological pathway.
Apart from the PDCD10-SERPINI1 gene pair at chromo-
some 3q26, there was another human head-to-head gene
pair found to be associated with brain diseases [35]. This
gene pair, consisting of the parkinsonism-related parkin
gene (PARK2) and parkin co-regulated gene (PACRG) at
chromosome 6q25.2-27, has many features in common
with the PDCD10-SERPINI1  pair. Like SERPINI1  and
PDCD10, PARK2 and PACRG are also non-homologous.
PARK2, like SERPINI1, has its tissue specificity and is
mainly expressed in brain, heart, skeletal muscle and kid-
ney. PACRG is expressed in all tissues like PDCD10. The
bidirectional promoter of PACRG-PARK2  is also TATA-
less, GC-rich, and with multiple Sp1 binding sites [35,36].
Furthermore, the genetic mutations of SERPINI1  and
PARK2  are able to accelerate the formation of cellular
inclusion bodies and to cause the dementia symptom
[18,21,37]. Therefore, we suggest that brain, being the
most sophisticated organ which controls almost all
responses of the whole body, may use bidirectional pro-
moters to achieve gene expressions more efficiently, espe-
cially in the pathogenesis of its diseases.
Gene expression and tissue specificity are often regulated
by transcriptional activators or repressors [38-40]. In the
case of the PDCD10-SERPINI1 gene pair, it is apparent
that these two genes are not co-expressed genes (Fig. 1).
This phenomenon can be best explained by the existence
of a critical fragment, from nt 176 to 473 of the intergenic
sequence, which contains an enhancer and a repressive
element to coordinately regulate the transcriptions of
both genes (Fig. 5 &6). The intergenic enhancer is orienta-
tion-dependent exerting its effect on the promoter of
PDCD10 in the native context (Fig. 5). It also works in an
orientation-dependent manner with heterologous pro-
moters (Fig. 6A &6B). Previously, a similar orientation-
dependent intergenic enhancer had been reported in a
mouse gene pair: the divergent Cryab (αB-crystallin) and
Hspb2 (heat shock 27 kDa protein 2) pair [41]. However,
this is the first time that such an enhancer is identified in
the human genome. Moreover, the neuron-specificity of
SERPINI1 and its down-regulation in brain tumorigenesis
may be accounted for by a repressive element located in
the same critical regulatory fragment (Fig. 5 &6). Together
these results suggest that the fine coordination between
the orientation-dependent cis-control elements may play
an important role in the asymmetrical expressions of
PDCD10 and SERPINI1 in different tissues. In addition to
the cis-control elements, the possible involvement of cer-
tain trans-acting factors in this bidirectional promoter
region need to be further elucidated.
Conclusion
Here we present evidence that two non-homologous
brain diseases-related genes, SERPINI1 and PDCD10, are
tightly linked in a divergent configuration by a bidirec-BMC Molecular Biology 2007, 8:2 http://www.biomedcentral.com/1471-2199/8/2
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tional promoter in an evolutionarily conserved fashion.
Within their tiny intergenic region, a segment from nt 1 to
175 near the vicinity of PDCD10 was identified to func-
tion as a minimal promoter to efficiently drive the expres-
sions of the two flanking genes. A critical regulatory
fragment from nt 176 to 473 was further determined to
contain a repressive element for SERPINI1  and an
enhancer for PDCD10 that coordinately regulate the tran-
scriptions of both genes. For all the non-homologous
genes that have been described to be closely adjacent in
the human genome, the intergenic region of the head-to-
head PDCD10-SERPINI1 gene pair at 3q26 exhibits an
interesting and informative example of a complex regula-
tory system that governs the expression of both genes not
only through an asymmetric bidirectional promoter, but
also through fine-tuned regulations with some cis-acting
elements.
Methods
Cell culture
All culture media, except RPMI 1640 medium, were pur-
chased from Gibco Invitrogen (Carlsbad, CA, USA) and
supplemented with 10% fetal bovine serum (FBS)
(HyClone, Logan, UT, USA). H4 (human neuroglioma)
and OVTW-59-4 (human ovarian adenocarcinoma) cells
were cultured in DMEM (Dulbecco's modified Eagle's
medium) medium, whereas U-87 MG (human brain
glioblastoma) and HeLa (human cervical adenocarci-
noma) cells were grown in minimum essential medium
(MEM). CL1-5 (high-metastatic human lung adenocarci-
noma) cells were cultured in RPMI-1640 medium
(Hyclone) supplemented with 0.5 mM L-glutamine and
10% FBS. PC-12 (rat adrenal gland pheochromocytoma)
cells were cultured in 85% RPMI-1640 supplemented
with 5% FBS and 10% horse serum. All cell lines were
maintained at 37°C in a humidified atmosphere of 5%
CO2 in air.
Northern blotting
Northern hybridizations were carried out mainly as
described previously [12]. In brief, the probe for
SERPINI1 was amplified from the FirstChoice PCR-Ready
human brain cDNA (Ambion, Austin, TX, USA) using the
forward primer 5'-CTGGAAGTCGCAGTTTAGGCCTGAA-
3' and the reverse primer 5'-TGGATGGTC-
GACAATAACTTGAGGA-3' to produce a 559-bp fragment
under the following conditions: 1 cycle of 94°C for 5 min;
32 cycles of 94°C for 20 sec, 55°C for 20 sec, and 72°C
for 1 min; and 1 cycle of 72°C for 10 min. The probe for
PDCD10 was amplified from the same cDNA using the
forward primer 5'-TCCATGGTTTCTATGCCCCT-3' and
the reverse primer 5'-TTTGGTGTTCAAGTGCCCTG-3' to
Table 1: Primer sequences used to amplify intergenic fragments for subsequent cloning
Construct* Primer sequence
(Forward) (Reverse)
pGL3-Basic constructs
1. SERPINI1 (1-851) 5'-ATAGATCTACTCCGGCGACGCCGGA-3' 5'-ATAAGCTTGTCCAGACTGCGCCTCT-3'
2. SERPINI1 (1-175) 5'-ATAGATCTACTCCGGCGACGCCGGA-3' 5'-ATAAGCTTTCGCCTCAGGATCCCCC-3'
3. SERPINI1 (176-851) 5'-CGAGATCTTGGGTGGTGACACTTCT-3' 5'-ATAAGCTTGTCCAGACTGCGCCTCT-3'
4. SERPINI1 (474-851) 5'-AGAGATCTGTGTGGGGACTTGCACT-3' 5'-ATAAGCTTGTCCAGACTGCGCCTCT-3'
5. SERPINI1 (711-851) 5'-ATAGATCTCAGGGCAGCTGCTTTCC-3' 5'-ATAAGCTTGTCCAGACTGCGCCTCT-3'
6. PDCD10 (851-1) 5'-ATAGATCTGTCCAGACTGCGCCTCT-3' 5'-ATAAGCTTACTCCGGCGACGCCGGA-3'
7. PDCD10 (710-1) 5'-TCAGATCTGTACCTTTCCGCTCCCT-3' 5'-ATAAGCTTACTCCGGCGACGCCGGA-3'
8. PDCD10 (473-1) 5'-ATAGATCTCAAGCCCTCCCTTCACC-3' 5'-ATAAGCTTACTCCGGCGACGCCGGA-3'
9. PDCD10 (175-1) 5'-ATAGATCTTCGCCTCAGGATCCCCC-3 5'-ATAAGCTTACTCCGGCGACGCCGGA-3'
10. PDCD10 (107-1) 5'-ATAGATCTGCCGGCGAGCGGGACTA-3' 5'-ATAAGCTTACTCCGGCGACGCCGGA-3'
11. PDCD10 (175-108) 5'-ATAGATCTTCGCCTCAGGATCCCCC-3' 5'-CCAAGCTTGTTGTCCGCAATTCCTG-3'
12. PDCD10 (851-176) 5'-ATAGATCTGTCCAGACTGCGCCTCT-3' 5'-CGAAGCTTTGGGTGGTGACACTTCT-3'
Heterologous promoter constructs
1. SERPINI1 (176-851)/S 5'-CCTGCTAGCTGGGTGGTGACACTTCTAG-3' 5'-AAAGATCTGTCCAGACTGCGCCTCTG-3'
2. PDCD10 (851-176)/S 5'-TAAGCTAGCGTCCAGACTGCGCCTCTG-3' 5'-CCTAGATCTTGGGTGGTGACACTTCTAG-3'
3. PDCD10 (473-176)/S 5'-TATGCTAGCCAAGCCCTCCCTTCACCTGG-3' 5'-CCTAGATCTTGGGTGGTGACACTTCTAG-3'
4. PDCD10 (710-474)/S 5'-GCTGCTAGCGTACCTTTCCGCTCCCTG-3' 5'-GAAGATCTGTGTGGGGACTTGCACTG-3'
5. PDCD10 (851-711)/S 5'-TAAGCTAGCGTCCAGACTGCGCCTCTG-3' 5'-TTAGATCTCAGGGCAGCTGCTTTCCG-3'
6. SERPINI1 (176-473)/C 5'-CCTGCTAGCTGGGTGGTGACACTTCTAG-3' 5'-CCAGATCTCAAGCCCTCCCTTCACCTGG-3'
7. SERPINI1 (474-710)/C 5'-GGAGCTAGCGTGTGGGGACTTGCA-3' 5'-CTAGATCTGTACCTTTCCGCTCCCTG-3'
8. SERPINI1 (711-851)/C 5'-CTTGCTAGCCAGGGCAGCTGCTTTCCG-3' 5'-AAAGATCTGTCCAGACTGCGCCTCTG-3'
*Construct names with an "S" character at the end indicates that the PCR-amplified intergenic product was cloned into the upstream of SV40 
minimal promoter. Construct names with a "C" character denotes that the amplified intergenic segment was cloned into the upstream of CMV 
promoter.BMC Molecular Biology 2007, 8:2 http://www.biomedcentral.com/1471-2199/8/2
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produce a 445-bp fragment under the following condi-
tions: 1 cycle of 94°C for 5 min; 35 cycles of 94°C for 30
sec, 55°C for 30 sec, and 72°C for 30 sec; and 1 cycle of
72°C for 10 min. All PCRs were performed on a T3 ther-
mocycler (Whatman Biometra, Goettingen, Germany)
using Ex Taq polymerase (Takara, Otsu, Singa, Japan) and
subjected to sequencing on an ABI PRISM 3700 auto-
mated sequencer (Applied Biosystems, Foster City, CA,
USA) by the core facility of the National Health Research
Institutes (Zhunan, Taiwan). The sequence-verified
probes, including a cDNA probe for ubiquitin supplied by
the manufacturer and used as a control, were labeled with
[α-32P]dCTP using the Rediprime II DNA labeling system
(Amersham/GE Healthcare, Piscataway, NJ, USA) fol-
lowed by hybridization against either the human MTE
multiple tissue expression array or cancer profiling array
(BD Bioscience Clontech, Palo Alto, CA, USA) in an
ExpressHyb hybridization solution (BD Bioscience Clon-
tech) for 4 h at 65°C. The arrays were then washed and
exposed to X-ray film for detection. Each Northern blot
analysis was repeated at least three times to confirm repro-
ducibility of the results.
Semi-quantitative reverse transcription polymerase chain 
reaction (RT-PCR)
Total RNAs were extracted from two human brain tumor
cell lines, H4 and U-87 MG, using TRIZOL reagent (Gibco
Invitrogen) followed by DNase (Ambion) treatment to
eliminate potential genomic DNA contamination. For
control, total RNA of normal brain tissue was obtained
from Clontech. Complementary DNA (cDNA) was syn-
thesized from 5 μg of total RNA using oligo(dT) priming
(Roche Molecular Biochemicals, Indianapolis, IN, USA)
and MMLV reverse transcriptase (Epicentre Technologies,
Madison, WI, USA). After a 1-h incubation at 37°C, the
reaction mixtures were heat inactivated at 92°C for 10
min and then applied as templates to amplify cDNAs spe-
cific for SERPINI1 (amplified with the forward primer 5'-
CTTGCAATGGGAATGATGGAACTTG-3' and the reverse
primer 5'-CGAAATCATGTCCACTTGTGTTCAT-3' at 1
cycle of 94°C for 5 min; 35 cycles of 94°C for 30 sec,
55°C for 30 sec, and 72°C for 90 sec; and 1 cycle of 72°C
for 10 min) and for PDCD10 (amplified with the forward
primer 5'-TCCATGGTTTCTATGCCCCT-3' and the reverse
primer 5'-TTTGGTGTTCAAGTGCCCTG-3' at 1 cycle of
94°C for 5 min; 35 cycles of 94°C for 30 sec, 55°C for 30
sec, and 72°C for 30 sec; and 1 cycle of 72°C for 10 min).
GAPDH serving as internal control was amplified using
the primer set 5'-CCTGCACCACCAACTGCTTA-3' and 5'-
ACCCTGTTGCTGTAGCCAAA-3' to allow comparison of
RNA levels among different samples. The PCR conditions
for GAPDH were the same as those for PDCD10.
5'-Rapid amplification of cDNA ends (RACE)
The 5'-RACE analysis was performed using the FirstChoice
human brain RNA ligase-mediated (RLM)-RACE kit
(Ambion). Two RNA adaptor primers were employed as
forward primers according to the manufacturer's instruc-
tion. The reverse primers for the 5'-RACE of SERPINI1
were 5'-TAGGCTGTCATATCCCATTGAGTGG-3' for the
outer primer and 5'-CAAGTTCCATCATTCCCATTGCAAG-
3' for the inner primer. The reverse primers for the 5'-
RACE of PDCD10  were 5'-CTCAGCTTCATTCT-
TCATCTCTTC-3' for the outer primer and 5'-CCTCAT-
TCAAAAGCCAACTACAG-3' for the inner primer. Both
the first and second rounds of PCR were performed with
1 cycle at 94°C for 3 min; 35 cycles at 94°C for 30 sec,
60°C for 30 sec, and 72°C for 30 sec; and 1 cycle at 72°C
for 7 min. The PCR products were cloned into a T-tailed
vector pGEM-T-Easy (Promega, Madison, WI, USA) fol-
lowed by sequencing to determine the 5'-ends of
SERPINI1 and PDCD10 transcripts.
Construction of the reporter gene plasmids
All restriction enzymes were purchased from Takara.
Genomic DNA was purified from human whole blood
samples using the QIAamp Blood kit (Qiagen, Hilden,
Germany). The various lengths of the intergenic segment
between SERPINI1 and PDCD10 were obtained by PCR
using the primers listed in Table 1 under the following
condition: 1 cycle of 94°C for 5 min; 35 cycles of 94°C for
30 sec, 55°C for 30 sec, and 72°C for 30 sec; and 1 cycle
of 72°C for 10 min. The amplified DNA fragments were
then cloned into one of the three vectors: pGL3-Basic,
pGL3-Promoter, or pGL3-Promoter with the original
SV40 promoter being replaced by a CMV promoter.
Transient transfection and promoter assays
Cells were first seeded in 12-well culture plates at a density
of 1.8 × 105 cells per well. Cells were then co-transfected
with 3 μl of Lipofectamine 2000 (Gibco Invitrogen) and a
mixture of 525 ng of DNA consisting of 500 ng of the
tested pGL3 promoter constructs and 25 ng of the pRL-TK
Renilla luciferase reporter plasmids (Promega) in a serum-
free medium. After a 3-h incubation at 37°C, the transfec-
tion medium was replaced with fresh medium supple-
mented with 10% FBS and cells were incubated for
another 24 h. After incubation, cells were washed twice
with PBS and lysed by reporter lysis buffer (Promega).
Cellular debris was removed after centrifugation at 10,000
× g for 5 min at 4°C. Cell extracts were then assayed for
luciferase activity using a SIRIUS luminometer (Berthold,
Bad Wildbad, Germany). In each experiment, cells were
transfected with pGL3-Basic and pGL3-Promter plasmids
that served as negative and positive control, respectively.
To normalize transfection efficiency, the pRL-TK plasmids
were co-transfected as an internal control.BMC Molecular Biology 2007, 8:2 http://www.biomedcentral.com/1471-2199/8/2
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Abbreviations
The abbreviations used are: SERPINI1, serine protease
inhibitor, clade I, member 1; PDCD10, programmed cell
death 10; PARK2, parkin; PACRG, parkin co-regulated
gene; CRYAB, αB-crystallin; HSPB2, heat shock 27 kDa
protein 2; FBS, fetal bovine serum; GAPDH, glyseralde-
hyde-3-phosphate dehydrogenase; RACE, rapid amplifi-
cation of cDNA ends; RT-PCR, reverse transcription-
polymerase chain reaction.
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